Promis Neurosciences (PMN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...

Eyelit Technologies (Eyelit), a leader in optimized planning, scheduling, and execution systems for manufacturers, today announced a migration program for manufacturers running PROMIS and ...

As of Wednesday, June 10, ProMIS Neurosciences, Inc.’s PMN share price has dipped by 6.72%, which has investors questioning ...

TORONTO, Ontario and CAMBRIDGE, Massachusetts , Sept. 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development ...

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and ...

ProMIS Neurosciences, a clinical-stage biotechnology company focused on developing therapeutic antibodies for neurodegenerative diseases, has announced a purchase agreement to issue approximately $2.4 ...

ProMIS Neurosciences Inc., a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases, announced progress in its clinical programs and shared insights from its ...

View ProMIS Neurosciences Inc. PMN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Manufacturers running legacy PROMIS or first-gen MES can apply 25% of current maintenance spend toward a modern Eyelit MOM/MES subscription. Eyelit Technologies (Eyelit), a leader in optimized ...

"2024 was a transformational year for ProMIS Neurosciences as we reached a major milestone with the initiation of our 100-patient Phase 1b clinical trial for PMN310, our lead antibody candidate for AD ...